Sitafloxacin is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Sitafloxacin directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Sitafloxacin remains protective as scientific knowledge develops.
ICH Q3A qualification thresholds for impurities in new drug substances require toxicological qualification of individual impurities of Sitafloxacin exceeding the reporting threshold (0.05% or 1 mg TDI, whichever is lower), identification threshold (0.10% or 2 mg TDI), and qualification threshold (0.15% or 2 mg TDI).
